- Home
- CAAP vs TARS Comparison
CAAP vs TARS Comparison
Compare CAAP & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAAP
- TARS
- Stock Information
- Founded
- CAAP 1998
- TARS 2016
- Country
- CAAP Luxembourg
- TARS United States
- Employees
- CAAP N/A
- TARS N/A
- Industry
- CAAP Aerospace
- TARS Medicinal Chemicals and Botanical Products
- Sector
- CAAP Consumer Discretionary
- TARS Health Care
- Exchange
- CAAP Nasdaq
- TARS Nasdaq
- Market Cap
- CAAP 2.9B
- TARS 2.8B
- IPO Year
- CAAP 2018
- TARS 2020
- Fundamental
- Price
- CAAP $23.16
- TARS $74.61
- Analyst Decision
- CAAP Strong Buy
- TARS Strong Buy
- Analyst Count
- CAAP 2
- TARS 7
- Target Price
- CAAP $24.60
- TARS $69.86
- AVG Volume (30 Days)
- CAAP 193.4K
- TARS 499.9K
- Earning Date
- CAAP 11-19-2025
- TARS 11-04-2025
- Dividend Yield
- CAAP N/A
- TARS N/A
- EPS Growth
- CAAP N/A
- TARS N/A
- EPS
- CAAP 0.93
- TARS N/A
- Revenue
- CAAP $1,873,095,000.00
- TARS $366,100,000.00
- Revenue This Year
- CAAP $4.43
- TARS $139.46
- Revenue Next Year
- CAAP $7.32
- TARS $49.91
- P/E Ratio
- CAAP $24.66
- TARS N/A
- Revenue Growth
- CAAP 26.88
- TARS 182.44
- 52 Week Low
- CAAP $15.01
- TARS $38.51
- 52 Week High
- CAAP $23.43
- TARS $76.81
- Technical
- Relative Strength Index (RSI)
- CAAP 75.05
- TARS 64.92
- Support Level
- CAAP $21.67
- TARS $65.93
- Resistance Level
- CAAP $22.36
- TARS $71.95
- Average True Range (ATR)
- CAAP 0.63
- TARS 3.08
- MACD
- CAAP 0.20
- TARS 0.18
- Stochastic Oscillator
- CAAP 93.66
- TARS 86.68
About CAAP Corporacion America Airports SA
Corporacion America Airports SA acquires, develops, and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador, and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.